Medical Specialties News
-
New Data Shows 85% Reduction in One-Year Mortality for Medicare Heart Failure Patients With BVA-Guided Care
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s leading experts in heart failure from ...
-
New Studies Validating the Uniqueness of the BVA-100 Blood Test for Heart Failure Patients Compared to Pressure Measures
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together ...
-
INTIN - Creator of a Male Sperm Analyzer and Ovulation Tester
The global fertility services market is estimated to reach $45 billion by 2027. This opens up a massive opportunity for startups to innovate in the space. One of the most innovative startups is INTIN, the creator of a male sperm analyzer called OVIEW-M, which uses the camera on a smartphone to analyze sperm counts. They are also the creators of an at-home ovulation tester that uses salvia instead ...
By INTIN Inc.
-
Lattice Medical announces the closing of a €8 million Series A financing round
LATTICE MEDICAL, announces the closing of a second round of financing of 8 million euros. This round was led by the historical funds Finovam Gestion, Nord France Amorçage and WiSEED alongside the Captech Santé fund. The European Commission, via its EIC Fund, and Santelys are co-investing. The financing round is completed by non-dilutive financing, in the form of a grant and debt ...
-
COVID-19 and flu ‘Twindemic’ could overwhelm hospitals this winter
Airfinity predicts a potential ‘twindemic’ of COVID-19 and flu could overwhelm hospitals this winter. The analysis focuses on two potential scenarios, based on data from previous winter COVID-19 waves driven by the Alpha and Omicron BA.1 variants as well as historical flu admissions from 2017-2018, the last bad flu season, as another bad flu season is expected this year based on ...
-
IMV Provides an Update on The VITALIZE Trial
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination ...
By IMV Inc.
-
BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...
-
FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
-
Diagnostics-4-Future Conference
Meet us from October 12 – 13, 2022 at the Diagnostics-4-Future conference in Konstanz and learn more about our know-how in the fields of contract manufacturing, contract development, lifecycle management and many more. Meet LRE Medical at booth #16 or if you would like to set an appointment, please reach out to Claudia Strehle at strehle@lre.de. Diagnostics-4-Future is an ...
By LRE Medical
-
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
-
SeqOne Genomics announces Portuguese distribution partnership
SeqOne Genomics, provider of next-generation genomic analysis solutions for personalized medicine is proud to announce a new strategic partnership with ILC Instrumentos de Laboratório Científicos to facilitate access to its genomic analysis solutions in Portugal. Through this partnership, ILC Instrumentos de Laboratório Científicos has been appointed as a value added ...
-
Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As communicated on 23 September 2021, ...
-
Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal
Results of an analysis of a previous prevention trial with Diamyd® (GAD-alum) treatment, which indicate a positive and sustained immunomodulating effect after treatment with Diamyd® in healthy children at risk for type 1 diabetes, have been published in the scientific journal Journal of Immunology Research. The analysis was carried out by researchers at Lund University and provides ...
-
Inversago Pharma Awarded the Promising Health Biotech Company of the Year Gold Leaf Award at the BIONATION Conference in Ottawa
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the ?Promising Health Biotech Company of the Year' Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada. An initiative of BIOTECanada, the national industry association, coveted Gold ...
-
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to $10.7 million of oral TPOXX (Contract number: W911SR22C0051), of which $5.1 million of oral TPOXX is ...
-
All patients in DiagnodE-B have received an additional (booster) injection of Diamyd
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. DIAGNODE-B (B for “booster”) assesses ...
-
Creative Medical Technology Announces Positive Top-Line Results for StemSpine Pilot Study
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive two-year follow-up data for the Company's StemSpine® pilot study, showing significant efficacy of the StemSpine® ...
-
New partner Continentia Association
In January 2017 we signed a collaboration agreement with Continentia Association. The Association, created by a group of specialists in the field of urology, focused on research of incontinence-related diseases and professional training in this field. Incorporating their experience and extensive knowledge is a great value to us. Dr. José Emilio Batista, president of the Association, is ...
-
Field Orthopaedics announces strategic alliance with Medartis Inc
The strategic alliance will see the NX Nail system from Field Orthopaedics added to Medartis’ comprehensive hand portfolio in an exclusive distribution partnership, which will extend the global distribution footprint of the product and provide growth opportunities in international markets. With an anatomically inspired head, narrow waist and cutting efficiency, the NX Nail is engineered to ...
-
Anuncia Medical, Inc., receives FDA clearance for the ReFlow System Mini for the treatment of patients with hydrocephalus
Anuncia Medical, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the ReFlow® System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid (CSF) disorders that require shunting. Anuncia Medical announced FDA clearance of ReFlow® System Mini for the treatment of cerebrospinal fluid (CSF) disorders. The FDA 510(k) clearance allows ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you